Multiparametric-Magnetic Resonance Imaging in Prostate Cancer Diagnosis

Tsitsino Abakelia, Ketevan Lashkhi, Sophio Kakhadze



Prostate cancer is the second most commonly occurring cancer in men. Early detection of prostate cancer impacts survival outcomes. Magnetic resonance imaging(MRI)- as a radiation-free diagnostic exam, is a valuable tool in radiology for detection and precise staging of clinically significant cancer- in men suspicious for prostate cancer(Pc). Background: there are several imaging tests of choice for Pc diagnosis, with certain advantages and disadvantages; The evolution of imaging techniques has created a new role for radiology tests. Multiparametric MRI approach proceeds to become widely used tool in preoperative prostate cancer evaluation, especially after the establishment of Prostate imaging-reporting and data system (pi rads) with fixed criteria, involving risk stratification for the presence or absence of clinically significant Pc. Objectives: This paper reviews major aspects of multiparametric MRI sequences for prostate cancer diagnosis in the existing literature. It describes the role of each advanced technique in MRI to define prostate cancer grade. Methods: a search for articles on prostate cancer multiparametric MRI was performed using the PubMed electronic database and 24 studies were included. Results: All the included articles showed that Magnetic resonance imaging (MRI) offers an increasingly reliable representation of significant Pc and thus has shown advantages as a means by which to assess the grade of tumor, define stage noninvasively and select patients for biopsy and facilitate direct targeting of lesions during the biopsy. Conclusion: This review highlights the potential of mpMRI in prostate cancer diagnosis in clinical practice, discusses data from existing literature, with a specific interpretation of MR sequences such as T2 weighted imaging, Diffusion-weighted imaging, Apparent diffusion coefficient, Dynamic contrast-enhanced MRI and MR spectroscopy.


Prostate cancer. Multiparametric-MRI. T2W imaging. Diffusion-weighted imaging. MR Spectroscopy. Dynamic Contrast-Enhanced MRI.

Full Text:



WHO. Source: Globocan 2020. Globocan 2020. 2020;

Shukla-Dave A, Hricak H. Role of MRI in prostate cancer detection. NMR Biomed. 2014;

Röthke M, Blondin D, Schlemmer HP, Franiel T. PI-RADS classification: Structured reporting for MRI of the prostate. RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der Bildgeb Verfahren. 2013;

Weinreb JC, Barentsz JO, Choyke PL, Cornud F, Haider MA, Macura KJ, et al. PI-RADS Prostate Imaging - Reporting and Data System: 2015, Version 2. Eur Urol. 2016;69(1).

Bonekamp D, Jacobs MA, El-Khouli R, Stoianovici D, Macura KJ. Advancements in MR imaging of the prostate: From diagnosis to interventions. Radiographics. 2011;31(3).

Akin O, Sala E, Moskowitz CS, Kuroiwa K, Ishill NM, Pucar D, et al. Transition zone prostate cancers: Features, detection, localization, and staging at endorectal MR imaging. Vol. 239, Radiology. 2006.

Murphy G, Haider M, Ghai S, Sreeharsha B. The expanding role of MRI in prostate cancer. In: American Journal of Roentgenology. 2013.

Ocak I, Bernardo M, Metzger G, Barrett T, Pinto P, Albert PS, et al. Dynamic contrast-enhanced MRI of prostate cancer at 3 T: a study of pharmacokinetic parameters. AJR Am J Roentgenol. 2007;189(4).

Maurer MH, Heverhagen JT. Diffusion weighted imaging of the prostate-principles, application, and advances. Translational Andrology and Urology. 2017.

Verma S, Rajesh A, Morales H, Lemen L, Bills G, Delworth M, et al. Assessment of aggressiveness of prostate cancer: Correlation of apparent diffusion coefficient with histologic grade after radical prostatectomy. Am J Roentgenol. 2011;

Lebovici A, Sfrangeu SA, Feier D, Caraiani C, Lucan C, Suciu M, et al. Evaluation of the normal-to-diseased apparent diffusion coefficient ratio as an indicator of prostate cancer aggressiveness. BMC Med Imaging. 2014;

Lawrence EM, Gallagher FA, Barrett T, Warren AY, Priest AN, Goldman DA, et al. Preoperative 3-T diffusion-weighted MRI for the qualitative and quantitative assessment of extracapsular extension in patients with intermediate- or high-risk prostate cancer. American Journal of Roentgenology. 2014.

Panebianco V, Barchetti F, Sciarra A, Musio D, Forte V, Gentile V, et al. Prostate cancer recurrence after radical prostatectomy: The role of 3-T diffusion imaging in multi-parametric magnetic resonance imaging. Eur Radiol. 2013;

Mazaheri Y, Akin O, Hricak H. Dynamic contrast-enhanced magnetic resonance imaging of prostate cancer: A review of current methods and applications. World J Radiol. 2017;

Villers A, Puech P, Mouton D, Leroy X, Ballereau C, Lemaitre L. Dynamic Contrast Enhanced, Pelvic Phased Array Magnetic Resonance Imaging of Localized Prostate Cancer for Predicting Tumor Volume: Correlation With Radical Prostatectomy Findings. J Urol. 2006;176(6).

Erbersdobler A, Isbarn H, Dix K, Steiner I, Schlomm T, Mirlacher M, et al. Prognostic value of microvessel density in prostate cancer: A tissue microarray study. World J Urol. 2010;28(6).

Padhani AR, MacVicar AD, Gapinski CJ, Dearnaley DP, Parker GJM, Suckling J, et al. Effects of androgen deprivation on prostatic morphology and vascular permeability evaluated with MR imaging. Radiology. 2001;218(2).

Young JC, Jeong KK, Kim N, Kyoung WK, Choi EK, Cho KS. Functional MR imaging of prostate cancer. Vol. 27, Radiographics. 2007.

Claus FG, Hricak H, Hattery RR. Pretreatment evaluation of prostate cancer: Role of MR imaging and 1H MR spectroscopy. Radiographics. 2004;24(SPEC. ISS.).

Wetter A, Engl TA, Nadjmabadi D, Fliessbach K, Lehnert T, Gurung J, et al. Combined MRI and MR spectroscopy of the prostate before radical prostatectomy. Am J Roentgenol. 2006;187(3).

Carroll PR, Coakley F V, Kurhanewicz J. Magnetic resonance imaging and spectroscopy of prostate cancer. Rev Urol. 2006;8 Suppl 1.

Presti JC. Prostate biopsy: current status and limitations. Rev Urol. 2007;

Kasivisvanathan V, Rannikko AS, Borghi M, Panebianco V, Mynderse LA, Vaarala MH, et al. MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis. N Engl J Med. 2018;

Bjurlin MA, Meng X, Le Nobin J, Wysock JS, Lepor H, Rosenkrantz AB, et al. Optimization of prostate biopsy: The role of magnetic resonance imaging targeted biopsy in detection, localization and risk assessment. Vol. 192, Journal of Urology. 2014.

Panebianco V, Barchetti F, Sciarra A, Ciardi A, Indino EL, Papalia R, et al. Multiparametric magnetic resonance imaging vs. standard care in men being evaluated for prostate cancer: A randomized study. Urol Oncol Semin Orig Investig. 2015;33(1).


  • There are currently no refbacks.


Become a REVIEWER 


ISSN: 2346-8491 (online)